Tokyo Tape
Sign in
← Chiome Bioscience

Annual report

4583.TEDINET S100XUJT
Period2025-01-01 → 2025-12-31
Filed2026-03-27
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 76
MetricValuePeriodScopeSource row
Revenue¥593m2025-01-01 → 2025-12-31StandaloneNet sales
Revenue¥781m2024-01-01 → 2024-12-31StandaloneNet sales
Revenue¥682m2023-01-01 → 2023-12-31vStandaloneNet sales (5-year summary)
Revenue¥631m2022-01-01 → 2022-12-31vStandaloneNet sales (5-year summary)
Revenue¥713m2021-01-01 → 2021-12-31dStandaloneNet sales (5-year summary)
Operating income−¥980m2025-01-01 → 2025-12-31StandaloneOperating income
Operating income−¥1.0bn2024-01-01 → 2024-12-31StandaloneOperating income
Ordinary income−¥989m2025-01-01 → 2025-12-31StandaloneOrdinary income
Ordinary income−¥1.0bn2024-01-01 → 2024-12-31StandaloneOrdinary income
Ordinary income−¥1.2bn2023-01-01 → 2023-12-31vStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥1.2bn2022-01-01 → 2022-12-31vStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥1.3bn2021-01-01 → 2021-12-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥980m2025-01-01 → 2025-12-31StandaloneIncome before income taxes
Profit before tax−¥1.0bn2024-01-01 → 2024-12-31StandaloneIncome before income taxes
Net income−¥983m2025-01-01 → 2025-12-31StandaloneProfit loss
Net income−¥1.0bn2024-01-01 → 2024-12-31StandaloneProfit loss
Net income−¥1.2bn2023-01-01 → 2023-12-31vStandaloneNet income loss (5-year summary)
Net income−¥1.2bn2022-01-01 → 2022-12-31vStandaloneNet income loss (5-year summary)
Net income−¥1.5bn2021-01-01 → 2021-12-31dStandaloneNet income loss (5-year summary)
Total assets¥1.7bnat 2025-12-31StandaloneAssets
Total assets¥2.5bnat 2024-12-31StandaloneAssets
Total assets¥1.8bnat 2023-12-31vStandaloneTotal assets (5-year summary)
Total assets¥2.2bnat 2022-12-31vStandaloneTotal assets (5-year summary)
Total assets¥2.3bnat 2021-12-31dStandaloneTotal assets (5-year summary)
Total liabilities¥605mat 2025-12-31StandaloneLiabilities
Total liabilities¥549mat 2024-12-31StandaloneLiabilities
Net assets / equity¥1.1bnat 2025-12-31StandaloneNet assets
Net assets / equity¥1.9bnat 2024-12-31StandaloneNet assets
Net assets / equity¥1.2bnat 2023-12-31vStandaloneNet assets
Net assets / equity¥1.8bnat 2022-12-31vStandaloneNet assets (5-year summary)
Net assets / equity¥1.9bnat 2021-12-31dStandaloneNet assets (5-year summary)
Cash and deposits¥1.2bnat 2025-12-31StandaloneCash and deposits
Cash and deposits¥2.1bnat 2024-12-31StandaloneCash and deposits
Cash & equivalents¥1.2bnat 2025-12-31StandaloneCash and cash equivalents
Cash & equivalents¥2.1bnat 2024-12-31StandaloneCash and cash equivalents
Cash & equivalents¥1.3bnat 2023-12-31vStandaloneCash and cash equivalents
Cash & equivalents¥1.7bnat 2022-12-31vStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥1.8bnat 2021-12-31dStandaloneCash and cash equivalents (5-year summary)
Operating cash flow−¥936m2025-01-01 → 2025-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.0bn2024-01-01 → 2024-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.1bn2023-01-01 → 2023-12-31vStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥1.2bn2022-01-01 → 2022-12-31vStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥1.1bn2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow−¥55m2025-01-01 → 2025-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow¥173,0002023-01-01 → 2023-12-31vStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥35m2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow¥133m2025-01-01 → 2025-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥1.7bn2024-01-01 → 2024-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥667m2023-01-01 → 2023-12-31vStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥1.1bn2022-01-01 → 2022-12-31vStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥271m2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥-14.472025-01-01 → 2025-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-17.542024-01-01 → 2024-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-24.622023-01-01 → 2023-12-31vStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-28.262022-01-01 → 2022-12-31vStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-36.742021-01-01 → 2021-12-31dStandaloneBasic earnings loss per share (5-year summary)
Net assets per share¥16.18at 2025-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥28.53at 2024-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥21.66at 2023-12-31vStandaloneNet assets per share (5-year summary)
Net assets per share¥36.7at 2022-12-31vStandaloneNet assets per share (5-year summary)
Net assets per share¥45.55at 2021-12-31dStandaloneNet assets per share (5-year summary)
Equity ratio64.1%at 2025-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio77.4%at 2024-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio65.1%at 2023-12-31vStandaloneEquity to asset ratio (5-year summary)
Equity ratio80.2%at 2022-12-31vStandaloneEquity to asset ratio (5-year summary)
Equity ratio79.4%at 2021-12-31dStandaloneEquity to asset ratio (5-year summary)
Shares issued68,453,800at 2025-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued66,969,000at 2024-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued52,640,200at 2023-12-31vStandaloneTotal number of issued shares (5-year summary)
Shares issued48,423,500at 2022-12-31vStandaloneTotal number of issued shares (5-year summary)
Shares issued40,781,500at 2021-12-31dStandaloneTotal number of issued shares (5-year summary)
Employees49at 2025-12-31StandaloneNumber of employees
Employees47at 2024-12-31StandaloneNumber of employees
Employees51at 2023-12-31vStandaloneNumber of employees
Employees49at 2022-12-31vStandaloneNumber of employees
Employees49at 2021-12-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 22
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment profit2025-01-01 → 2025-12-31−¥559m
Drug Discovery And Developmentreportable segmentsegment profit2025-01-01 → 2025-12-31−¥777m
Drug Discovery Supportreportable segmentdepreciation2025-01-01 → 2025-12-31¥4m
Drug Discovery Supportreportable segmentrevenue2025-01-01 → 2025-12-31¥593m
Drug Discovery Supportreportable segmentrevenue external2025-01-01 → 2025-12-31¥593m
Drug Discovery Supportreportable segmentsegment profit2025-01-01 → 2025-12-31¥356m
—segment totalemployeesat 2025-12-3139 pure
Total Of Reportable Segments And Otherssegment totaldepreciation2025-01-01 → 2025-12-31¥4m
Total Of Reportable Segments And Otherssegment totalrevenue2025-01-01 → 2025-12-31¥593m
Total Of Reportable Segments And Otherssegment totalrevenue external2025-01-01 → 2025-12-31¥593m
Total Of Reportable Segments And Otherssegment totalsegment profit2025-01-01 → 2025-12-31−¥421m
Reconciling Itemsreconcilingdepreciation2024-01-01 → 2024-12-31¥1m
Reconciling Itemsreconcilingsegment profit2024-01-01 → 2024-12-31−¥527m
Drug Discovery And Developmentreportable segmentrevenue2024-01-01 → 2024-12-31¥203m
Drug Discovery And Developmentreportable segmentrevenue external2024-01-01 → 2024-12-31¥203m
Drug Discovery And Developmentreportable segmentsegment profit2024-01-01 → 2024-12-31−¥814m
Drug Discovery Supportreportable segmentrevenue2024-01-01 → 2024-12-31¥578m
Drug Discovery Supportreportable segmentrevenue external2024-01-01 → 2024-12-31¥578m
Drug Discovery Supportreportable segmentsegment profit2024-01-01 → 2024-12-31¥310m
Total Of Reportable Segments And Otherssegment totalrevenue2024-01-01 → 2024-12-31¥781m
Total Of Reportable Segments And Otherssegment totalrevenue external2024-01-01 → 2024-12-31¥781m
Total Of Reportable Segments And Otherssegment totalsegment profit2024-01-01 → 2024-12-31−¥504m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 832
ItemContextValueUnit
Accrued expensesCurrentYearInstant_NonConsolidatedMember14555000JPY
Income taxes payablePrior1YearInstant_NonConsolidatedMember2531000JPY
Income taxes payableCurrentYearInstant_NonConsolidatedMember12553000JPY
Contract liabilitiesPrior1YearInstant_NonConsolidatedMember－JPY
Contract liabilitiesCurrentYearInstant_NonConsolidatedMember130329000JPY
Deposits receivedPrior1YearInstant_NonConsolidatedMember14543000JPY
Deposits receivedCurrentYearInstant_NonConsolidatedMember10787000JPY
Current liabilitiesPrior1YearInstant_NonConsolidatedMember493432000JPY
Current liabilitiesCurrentYearInstant_NonConsolidatedMember374885000JPY
Asset retirement obligations nclPrior1YearInstant_NonConsolidatedMember55120000JPY
Asset retirement obligations nclCurrentYearInstant_NonConsolidatedMember55554000JPY
Bonds payablePrior1YearInstant_NonConsolidatedMember－JPY
Bonds payableCurrentYearInstant_NonConsolidatedMember175000000JPY
Noncurrent liabilitiesPrior1YearInstant_NonConsolidatedMember55120000JPY
Noncurrent liabilitiesCurrentYearInstant_NonConsolidatedMember230554000JPY
LiabilitiesPrior1YearInstant_NonConsolidatedMember548553000JPY
LiabilitiesCurrentYearInstant_NonConsolidatedMember605440000JPY
Capital stockPrior1YearInstant_NonConsolidatedMember995525000JPY
Capital stockCurrentYearInstant_NonConsolidatedMember1085523000JPY
Legal capital surplusPrior1YearInstant_NonConsolidatedMember1935799000JPY
Legal capital surplusCurrentYearInstant_NonConsolidatedMember2025797000JPY
Capital surplusPrior1YearInstant_NonConsolidatedMember1935799000JPY
Capital surplusCurrentYearInstant_NonConsolidatedMember2025797000JPY
Retained earnings brought forwardPrior1YearInstant_NonConsolidatedMember-1020776000JPY
Retained earnings brought forwardCurrentYearInstant_NonConsolidatedMember-2003555000JPY
Retained earningsPrior1YearInstant_NonConsolidatedMember-1020776000JPY
Retained earningsCurrentYearInstant_NonConsolidatedMember-2003555000JPY
Treasury stockPrior1YearInstant_NonConsolidatedMember-292000JPY
Treasury stockCurrentYearInstant_NonConsolidatedMember-292000JPY
Shareholders equityPrior1YearInstant_NonConsolidatedMember1910255000JPY
Shareholders equityCurrentYearInstant_NonConsolidatedMember1107473000JPY
Subscription rights to sharesPrior1YearInstant_NonConsolidatedMember10048000JPY
Subscription rights to sharesCurrentYearInstant_NonConsolidatedMember14591000JPY
Net assetsPrior1YearInstant_NonConsolidatedMember1920303000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember1122064000JPY
Liabilities and net assetsPrior1YearInstant_NonConsolidatedMember2468857000JPY
Liabilities and net assetsCurrentYearInstant_NonConsolidatedMember1727504000JPY
Net salesPrior1YearDuration_NonConsolidatedMember780809000JPY
Net salesCurrentYearDuration_NonConsolidatedMember593290000JPY
Cost of salesPrior1YearDuration_NonConsolidatedMember347957000JPY
Cost of salesCurrentYearDuration_NonConsolidatedMember237707000JPY
Gross profitPrior1YearDuration_NonConsolidatedMember432851000JPY
Gross profitCurrentYearDuration_NonConsolidatedMember355583000JPY
Research and development expenses sgaPrior1YearDuration_NonConsolidatedMember936737000JPY
Research and development expenses sgaCurrentYearDuration_NonConsolidatedMember776536000JPY
Other sgaPrior1YearDuration_NonConsolidatedMember526984000JPY
Other sgaCurrentYearDuration_NonConsolidatedMember558821000JPY
Selling general and administrative expensesPrior1YearDuration_NonConsolidatedMember1463721000JPY
Selling general and administrative expensesCurrentYearDuration_NonConsolidatedMember1335358000JPY
Operating incomePrior1YearDuration_NonConsolidatedMember-1030869000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 13 of 13 passed
balance sheet identitynon_consolidated 2024-12-31pass rounding
balance sheet identitynon_consolidated 2025-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2023-12-31pass
statement vs summary · net assetsnon_consolidated 2024-12-31pass
statement vs summary · net assetsnon_consolidated 2025-12-31pass
statement vs summary · operating cash flownon_consolidated 2024-01-01/2024-12-31pass
statement vs summary · operating cash flownon_consolidated 2025-01-01/2025-12-31pass
statement vs summary · revenuenon_consolidated 2024-01-01/2024-12-31pass
statement vs summary · revenuenon_consolidated 2025-01-01/2025-12-31pass
statement vs summary · total assetsnon_consolidated 2024-12-31pass
statement vs summary · total assetsnon_consolidated 2025-12-31pass